Cargando…

Evidence for the Prevention and Treatment of Stroke in Dialysis Patients

The risks of both ischemic and hemorrhagic stroke are particularly high in dialysis patients of any age and outcomes are poor. It is therefore important to identify strategies that safely minimize stroke risk in this population. Observational studies have been unable to clarify the relative importan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrington, William, Haynes, Richard, Staplin, Natalie, Emberson, Jonathan, Baigent, Colin, Landray, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2015
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320775/ https://www.ncbi.nlm.nih.gov/pubmed/25040468 http://dx.doi.org/10.1111/sdi.12281

Ejemplares similares

Cross-sectional associations between central and general adiposity with albuminuria: observations from 400,000 people in UK Biobank
por: Zhu, Pengfei, et al.
Publicado: (2020)

Impact of Educational Attainment on Health Outcomes in Moderate to Severe CKD
por: Morton, Rachael L., et al.
Publicado: (2016)

Evaluating the Contribution of the Cause of Kidney Disease to Prognosis in CKD: Results From the Study of Heart and Renal Protection (SHARP)
por: Haynes, Richard, et al.
Publicado: (2014)

Impact of Outcome Adjudication in Kidney Disease Trials: Observations From the Study of Heart and Renal Protection
por: Herrington, William G., et al.
Publicado: (2023)

Campath, calcineurin inhibitor reduction, and chronic allograft nephropathy (the 3C Study) – results of a randomized controlled clinical trial
por: Haynes, Richard, et al.
Publicado: (2018)

Allocated but not treated: the silent 16% – Authors' reply
por: Horby, Peter, et al.
Publicado: (2022)

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation
por: Storey, Benjamin C., et al.
Publicado: (2018)

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy
por: Storey, Benjamin C., et al.
Publicado: (2018)

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease
por: Herrington, William, et al.
Publicado: (2017)

Impact of CKD on Household Income
por: Morton, Rachael L., et al.
Publicado: (2017)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
por: Staplin, Natalie, et al.
Publicado: (2021)

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP)
por: Staplin, Natalie, et al.
Publicado: (2016)

Determining the Relationship Between Blood Pressure, Kidney Function, and Chronic Kidney Disease: Insights From Genetic Epidemiology
por: Staplin, Natalie, et al.
Publicado: (2022)

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2019)

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection
por: Mafham, Marion M, et al.
Publicado: (2018)

Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the Study of Heart and Renal Protection (SHARP)
por: Mihaylova, Borislava, et al.
Publicado: (2016)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2018)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
por: Herrington, William G, et al.
Publicado: (2019)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
por: Schlackow, Iryna, et al.
Publicado: (2017)

What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?
por: Kent, Seamus, et al.
Publicado: (2015)

Accelerometer-measured physical activity and functional behaviours among people on dialysis
por: Nawab, Khizr A, et al.
Publicado: (2020)

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection
por: Reith, C., et al.
Publicado: (2017)

Tocilizumab in COVID-19 therapy: who benefits, and how? – Authors' reply
por: Horby, Peter, et al.
Publicado: (2021)

Estimated Glomerular Filtration Rate and the Risk of Major Vascular Events and All-Cause Mortality: A Meta-Analysis
por: Mafham, Marion, et al.
Publicado: (2011)

Neprilysin inhibition in chronic kidney disease
por: Judge, Parminder, et al.
Publicado: (2015)

Comparison of the Accuracy and Completeness of Records of Serious Vascular Events in Routinely Collected Data vs Clinical Trial–Adjudicated Direct Follow-up Data in the UK: Secondary Analysis of the ASCEND Randomized Clinical Trial
por: Harper, Charlie, et al.
Publicado: (2021)

Reliability of major bleeding events in UK routine data versus clinical trial adjudicated follow-up data
por: Harper, Charlie, et al.
Publicado: (2023)

Chronic kidney disease, heart failure and neprilysin inhibition
por: Haynes, Richard, et al.
Publicado: (2020)

Fibroblast Growth Factor-23 and Risk of Cardiovascular Diseases: a Mendelian Randomization study
por: Donovan, Killian, et al.
Publicado: (2023)

Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies
por: Wong, Germaine, et al.
Publicado: (2016)

Can vascular mortality be reliably ascertained from the underlying cause of death recorded on a medical death certificate? Evidence from 2800 adjudicated heart protection study (HPS) deaths
por: Herrington, William, et al.
Publicado: (2015)

The role of lipoprotein (a) in chronic kidney disease
por: Hopewell, Jemma C., et al.
Publicado: (2018)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Increasing the use of mobile technology–derived endpoints in clinical trials
por: Herrington, William G, et al.
Publicado: (2018)

Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom
por: Hopewell, Jemma C, et al.
Publicado: (2020)

What is the association of COVID-19 with heart attacks and strokes?
por: Mafham, Marion, et al.
Publicado: (2021)

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials
por: Scally, Benjamin, et al.
Publicado: (2018)

Campath, calcineurin inhibitor reduction and chronic allograft nephropathy (3C) study: background, rationale, and study protocol
por: Haynes, Richard, et al.
Publicado: (2013)

Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study
por: Herrington, William G, et al.
Publicado: (2018)

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study
por: Parish, Sarah, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5t6hi0r1pclsfm322ggvmj3u8s